WHO ICTRP trial
Donafenib and Toripalimab in combination with transarterial chemoembolization…
ChiCTR2100049493 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2100049493 |
|---|---|
| Public title | Donafenib and Toripalimab in combination with transarterial chemoembolization and bronchial arterial chemoinfusion Versus Donafenib and Toripalimab in the treatment of hepatocellular carcinoma with pulmonary metastasis: a randomized controlled trial |
| Scientific title | Donafenib and Toripalimab in combination with transarterial chemoembolization and bronchial arterial chemoinfusion Versus Donafenib and Toripalimab in the treatment of hepatocellular carcinoma with pulmonary metastasis: a randomized controlled trial |
| Primary sponsor | Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Hepatocellular carcinoma |
| Interventions | experimental group:TACE?BAI combined with donafinib and triprizumab ;control group:donafinib and triprizumab |
| Registration date | Aug 2, 2021 |
| Target size | experimental group:65;control group:65 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: